Profile data is unavailable for this security.
About the company
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
- Revenue in CHF (TTM)--
- Net income in CHF--
- Incorporated2022
- Employees23.85k
- LocationSandoz Group AGSuurstoffi 14ROTKREUZ 6343SwitzerlandCHE
- Websitehttps://www.sandoz.com/
More ▼
Mergers & acquisitions
| Acquired company | SDZ:SWX since announced | Transaction value |
|---|---|---|
| Coherus BioSciences Inc-CIMERLI Business | 12.42% | 170.00m |
Data delayed at least 15 minutes, as of May 08 2024 16:46 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Croda International Plc | 1.92bn | 194.03m | 7.71bn | 5.85k | 39.76 | 2.89 | 22.76 | 4.01 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
| Swedish Orphan Biovitrum AB (publ) | 1.93bn | 178.47m | 8.37bn | 1.75k | 45.82 | 2.69 | 18.09 | 4.34 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Qiagen NV | 1.78bn | 309.93m | 8.65bn | 5.97k | 28.20 | 2.50 | 17.43 | 4.85 | 1.42 | 1.42 | 8.18 | 16.01 | 0.3169 | 1.93 | 5.38 | 306,528.60 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Ipsen SA | 3.23bn | 602.12m | 9.55bn | 5.33k | 15.80 | 2.53 | 10.22 | 2.96 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Recordati Industria Chmc Frmctc SpA | 2.03bn | 379.76m | 10.45bn | 4.46k | 27.20 | 6.25 | 19.91 | 5.14 | 1.88 | 1.88 | 10.08 | 8.19 | 0.5075 | 1.59 | 5.16 | 467,414.40 | 9.48 | 11.67 | 12.40 | 15.02 | 68.32 | 70.43 | 18.69 | 21.45 | 0.795 | 8.34 | 0.5175 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Eurofins Scientific SE | 6.36bn | 503.96m | 10.85bn | 61.80k | 22.07 | 2.18 | 9.82 | 1.71 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
| BioMerieux SA | 3.59bn | 348.92m | 11.44bn | 14.65k | 32.93 | 3.12 | 19.03 | 3.19 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sandoz Group AG | -100.00bn | -100.00bn | 13.57bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Genmab A/S | 2.32bn | 713.20m | 17.33bn | 2.29k | 24.19 | 4.02 | -- | 7.46 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of May 08 2024. Currency figures normalised to Sandoz Group AG's reporting currency: Swiss Franc CHF
18.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 15.95m | 3.70% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 12.57m | 2.92% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 10.49m | 2.43% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 7.52m | 1.74% |
| GQG Partners LLCas of 31 Jan 2024 | 7.29m | 1.69% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 6.78m | 1.57% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 5.34m | 1.24% |
| J.O. Hambro Capital Management Ltd.as of 31 Mar 2024 | 4.32m | 1.00% |
| Eleva Capital LLPas of 31 Dec 2023 | 4.05m | 0.94% |
| Artisan Partners LPas of 31 Dec 2023 | 3.98m | 0.92% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
